Furthermore, we showed that tirzepatide is a biased agonist towards G s signaling and displayed similar activation of the wildtype and E354Q GIP receptor variants
This observation was based on results from wound healing assays, tests designed to measure various aspects of wound healing
Lilly has another candidate further ahead in development outside China that is taking up more of its R&D investment, namely retatrutide, a triple-acting agent that targets GLP-1, GIP, and glucagon in one molecule and is in several phase 3 trials across weight loss, diabetes, obstructive sleep apnoea, osteoarthritis, and chronic lower back pain, as well as for reducing the risk of cardiovascular and kidney complications in people with obesity
Both medications belong to a class of drugs known as incretin mimetics, which mimic the action of hormones that stimulate insulin release in response to food intake